Would you make if you were Jane Barrow? Why that one? If I were Jane Barrow‚ I would suggest shale gas as the best. Since the industrial‚ electric power and residential make a large contribution for the use of natural gas‚ the stakeholder in these parts are very important. After multiattribute risk analysis‚ the chart from Exhibit 10 shows they are care about using energy produced in their own jurisdiction. From the Exhibit 3‚ with the increasing need of natural gas to satisfy consumption‚ more
Premium Natural gas Coal Petroleum
GENZYME´S CSR DILEMMA: HOW TO PLAY ITS HANDS 1. INTRODUCTION Twenty years ago and earlier‚ with rare exceptions‚ the only corporate charity was a bit of gifting by the CEO‚ perhaps to the arts. Ten years ago‚ corporate philanthropy and volunteerism became popular as an a la carte add on. In these posts from the Clinton Global Initiative (CGI)‚ I am turning the spotlight on the avant garde of CSR: companies that make community and global problem-solving part of their business platform‚ thus
Premium Malaria Neglected diseases Project management
Case: Genzyme Corporation Problem: High equity financing company Genzyme has a tradition to be financed with equity. High equity ratio has advantages such as low agency costs related to debt‚ lower financial stress and more flexibility for management‚ which is especially crucial for start-up companies‚ such as in the early stage of Genzyme. However‚ besides losing the tax shield from debt‚ high equity financing leads to an increasingly diffused ownership‚ which would in turn causes problems such
Premium Stock market Information asymmetry Finance
ENT4400 – SUMMARY + REFLECTION Case study: Genzyme‚ schilling‚ chapter 6 page 105-109 Summary of the case: Genzyme was founded in 1981‚ Sanofi purchased the company in 2011. They went public in 1986‚ raising 27 million dollars. Genzyme startet as a start up Company by scientists studying genetically inherited enzyme diseases. Their strategy didn’t focus on the “blockbuster drugs” like other biotechnology companies but drugs for rare diseases. To developing a drug‚ it takes 10-14 years at
Premium Pharmacology Pharmaceutical drug Biotechnology
Genzyme Corp. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders‚ renal diseases‚ orthopedics‚ cancers‚ transplant and immune diseases‚ and diagnostic and predictive testing areas. Its leading drugs are Cerezyme‚ Fabrazyme‚ Myozyme‚ Aldurazyme‚ Elaprase‚ Renagel and Renvela‚ and many others. It has about 7‚000 employees. The current Chairman‚ President‚ & CEO is Henri A. Termeer. The company was founded in 1981 and is based in Cambridge
Premium Biogen Idec Biotechnology
from competition by focusing on orphan drugs. Also‚ the Orphan Drug Act provides 7 years of market exclusivity which virtually eliminates competition for Genzyme for at least a while. As an orphan drug‚ there is minimal threat of substitutes and potential entrants into the market‚ as explained above. Also‚ the nature of the drugs made by Genzyme are of a very critical nature; the drugs save lives of people with very rare genetic disorders. Considering these points‚ the bargaining power of customers
Premium Orphan drug Clinical trial Drug discovery
Case Analysis: Genzyme’s CSR Dilemma: How to Play its HAND. Background Considered a leader in the biotechnology industry‚ Genzyme has come a long way since its inception as a supplier of basic chemicals and reagents in 1981. As a leader in the development of orphan drugs‚ Genzyme realized revenues of almost $4B in 2007. Greater than 30% of its revenue in 2007 is attributed to the sales of drugs that target orphan diseases‚ such as Cerezyme‚ a novel Genzyme drug used to treat Gaucher disease
Premium Orphan drug Brazil Government
to purchase a U.S. biotech company as rumors circulate about Genzyme. 7/29/2010- Sanofi sends a private letter to Genzyme’s board of directors offering $69/share in cash. 8/22/2010- Genzyme rejects Sanofi’s offer. 8/29/2010- Sanofi goes public with its offer of $69/share. 8/30/2010- Genzyme publicly rejects Sanofi’s offer once again. 10/4/2010- Sanofi goes hostile and begins to directly solicit to Genzyme shareholders maintaining the $69/share value. The offer is
Premium Pharmaceutical industry Stock market Stock
Genzyme Case Study: Table of Contents Problem Identification......................................................................................................3 Alternative Solutions.........................................................................................................4 Recommendations.............................................................................................................5
Premium Cash flow Stock Investment
Analysis of Genzyme Waterford Student Names: Fiona Mallon and Hazel Mc Partlan Course: BA (Hons) in Marketing‚ Advertising and Online Media Module: Organisational Behaviour Submission Date: 11th of April 2013 Word Count: 3218 Total Word Count: 7980 We declare that this work is our own and of the highest academic integrity. Where the work of others has been used‚ it is properly acknowledged and referenced Table of Contents 1. Brief History of Genzyme 3 2. Practice of Motivational
Premium Maslow's hierarchy of needs